Merck & Co., Inc.
MRKNYSE · SIC 2834
$127.50
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +59.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$315.2B
Enterprise Value
$358.6B
P/E
35.9
P/S
4.8
P/B
6.9
EV/EBITDA
—
PEG
4.3
FCF Yield
4.5%
Dividend Yield
2.6%
Revenue (TTM)
$65.8B
Net Income (TTM)
$8.9B
Free Cash Flow (TTM)
$14.1B
Gross Margin
—
Operating Margin
—
Net Margin
13.6%
ROE
19.5%
ROIC
—
Debt / Equity
1.1
Net Cash
-$43.4B
Return 1Y
+61.6%
Company profile
Merck & Co. operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services.
- CEO
- Robert M. Davis
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 69,000
- Headquarters
- New Jersey
- Website
- merck.com
Management & directors
- Maraldo David R.EVP & Pres. MMD
- Smart DaltonSVP Fin. - Global Controller
- Larson Betty DEVP, Chief HR Officer
- Chattopadhyay SanatExe V-P & Pres. MMD
- Davis Robert MChairman, CEO & President
- Deluca Richard R.EVP&Pres, Merck Animal Heallth
- Guindo ChirfiEVP, Access, Policy & Comms
- Li Dean YExecutive VP & President, MRL
- Litchfield CarolineEVP & CFO
- Oosthuizen Johannes JacobusPresident, U.S. Market
- Williams David MichaelEVP,Chief Info&Digital Officer
- Zachary JenniferEVP, General Counsel
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
MRK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$16.3B↑ +4.9%
Diluted EPS-$1.72↓ -185.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.5B | $48.7B | $59.3B | $60.1B | $64.2B | $65.0B |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | $7.1B | $12.3B | $14.5B | $365.0M | $17.1B | $18.3B |
| Diluted EPS | $2.78 | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 |
| Operating cash flow | $10.3B | — | $19.1B | $13.0B | $21.5B | $16.5B |
| Free cash flow | — | — | $14.7B | $9.1B | $18.1B | $12.4B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | 17.0% | 25.3% | 24.5% | 0.6% | 26.7% | 28.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1B | $16.7B | $15.6B | $15.5B | $15.8B | $17.3B | $16.4B | $16.3B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $5.5B | $3.2B | $3.7B | $5.1B | $4.4B | $5.8B | $3.0B | -$4.2B |
| Diluted EPS | $2.14 | $1.24 | $1.49 | $2.01 | $1.76 | $2.32 | $1.19 | -$1.72 |
| Operating cash flow | $5.6B | $9.3B | $3.5B | $2.5B | $3.3B | $7.8B | $2.9B | $3.9B |
| Free cash flow | $4.8B | $8.5B | $2.5B | $1.2B | $2.5B | $6.8B | $1.8B | $2.9B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 33.9% | 19.0% | 24.0% | 32.7% | 28.0% | 33.5% | 18.1% | -26.0% |
Company news
Jul 20, 2026
- 1h agoReading Between The Lines Of JNJ Stock's Latest Calltrefis.com
- 1h agoMerck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.finance.yahoo.com
- 2h agoEli Lilly Stock And The Price Of Confidencetrefis.com
- 3h agoTempus AI Scoops Up Personalis For $1.5 Billion; But Shares Divefinance.yahoo.com
- 14h agoWhat Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.finance.yahoo.com
Jul 19, 2026
Jul 17, 2026
- 2d agoThe Real Question Buried Inside Merck Stock's Premium Pricetrefis.com
- 2d agoMerck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.finance.yahoo.com
- 3d agoGilead Leads The Battle Vs. HIV. But Rivals Are On The Move.finance.yahoo.com
- 3d agoMRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pillfinance.yahoo.com
- 3d agoThe First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?247wallst.com
- 3d agoMRNA Advances Cancer Pipeline With New Immunotherapy Studyfinance.yahoo.com
- 3d agoNew Cholesterol Pill, Earnings Growth Boost Merck Sharesfinance.yahoo.com
- 3d agoMSD wins FDA approval for cholesterol pill to help plug Keytruda voidpharmaceutical-technology.com
- 3d agoGSK shelves cough drug acquired in $2B dealbiopharmadive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-02 | Maraldo David R.· EVP & Pres. MMD | Option exercise | 552 | $112.16 | $61,912.32 | filing |
| 2026-05-02 | Smart Dalton· SVP Fin. - Global Controller | Option exercise | 383 | $112.16 | $42,957.28 | filing |
| 2026-05-02 | Maraldo David R.· EVP & Pres. MMD | Tax withholding | 159 | $112.16 | $17,833.44 | filing |
| 2026-05-02 | Smart Dalton· SVP Fin. - Global Controller | Tax withholding | 132 | $112.16 | $14,805.12 | filing |
| 2026-04-30 | Larson Betty D· EVP, Chief HR Officer | Option exercise | 11,350 | $110.95 | $1.3M | filing |
| 2026-04-30 | Larson Betty D· EVP, Chief HR Officer | Tax withholding | 5,143 | $110.95 | $570,615.85 | filing |
| 2026-04-30 | Smart Dalton· SVP Fin. - Global Controller | Option exercise | 464 | $110.95 | $51,480.80 | filing |
| 2026-04-30 | Smart Dalton· SVP Fin. - Global Controller | Tax withholding | 159 | $110.95 | $17,641.05 | filing |
| 2026-04-29 | Davis Robert M· Chairman, CEO & President | Option exercise | 13,300 | $110.03 | $1.5M | filing |
| 2026-04-29 | Davis Robert M· Chairman, CEO & President | Tax withholding | 6,551 | $110.03 | $720,806.53 | filing |
| 2026-04-29 | Li Dean Y· Executive VP & President, MRL | Option exercise | 4,722 | $110.03 | $519,561.66 | filing |
| 2026-04-29 | Litchfield Caroline· EVP & CFO | Option exercise | 3,935 | $110.03 | $432,968.05 | filing |
| 2026-04-29 | Zachary Jennifer· EVP, General Counsel | Option exercise | 2,951 | $110.03 | $324,698.53 | filing |
| 2026-04-29 | Chattopadhyay Sanat· Exe V-P & Pres. MMD | Option exercise | 2,597 | $110.03 | $285,747.91 | filing |
| 2026-04-29 | DeLuca Richard R.· EVP&Pres, Merck Animal Heallth | Option exercise | 2,518 | $110.03 | $277,055.54 | filing |
| 2026-04-29 | Li Dean Y· Executive VP & President, MRL | Tax withholding | 2,326 | $110.03 | $255,929.78 | filing |
| 2026-04-29 | Larson Betty D· EVP, Chief HR Officer | Option exercise | 2,085 | $110.03 | $229,412.55 | filing |
| 2026-04-29 | Guindo Chirfi· EVP, Access, Policy & Comms | Option exercise | 1,967 | $110.03 | $216,429.01 | filing |
| 2026-04-29 | Litchfield Caroline· EVP & CFO | Tax withholding | 1,938 | $110.03 | $213,238.14 | filing |
| 2026-04-29 | Zachary Jennifer· EVP, General Counsel | Tax withholding | 1,454 | $110.03 | $159,983.62 | filing |
| 2026-04-29 | Oosthuizen Johannes Jacobus· EVP, Oncology & Int?l | Option exercise | 1,377 | $110.03 | $151,511.31 | filing |
| 2026-04-29 | Williams David Michael· EVP,Chief Info&Digital Officer | Option exercise | 1,377 | $110.03 | $151,511.31 | filing |
| 2026-04-29 | DeLuca Richard R.· EVP&Pres, Merck Animal Heallth | Tax withholding | 1,241 | $110.03 | $136,547.23 | filing |
| 2026-04-29 | Chattopadhyay Sanat· Exe V-P & Pres. MMD | Tax withholding | 1,130 | $110.03 | $124,333.90 | filing |
| 2026-04-29 | Guindo Chirfi· EVP, Access, Policy & Comms | Tax withholding | 969 | $110.03 | $106,619.07 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.